Full Press Release Details
AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer
MD - February 26, 2024 - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"),
a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development
of pharmaceuticals and biologics, today announced the appointment of Dr. Thomas W. Chittenden, PhD, DPhil, PStat, as its new Chief Scientific
Officer. With a distinguished career at the intersection of artificial intelligence, machine learning, drug discovery, and biostatistics,
Dr. Chittenden brings a wealth of experience and a proven track record of leadership in scientific research and development to BullFrog
joining BullFrog AI, Dr. Chittenden served as the Chief Scientific Officer and President of Research and Development at BioAI Health,
a biotechnology company employing world-leading AI technology to map the causal biology of disease, develop digital biomarkers and identify
novel drug targets for the development of better medicine. While at BioAI Health, Dr. Chittenden led global scientific research operations
and oversaw the ongoing development and implementation of the PREDICT-X Drug Discovery and Development Platform. His leadership was instrumental
in advancing BioAI Health's mission to revolutionize drug discovery through innovative AI technologies.
to his role at BioAI Health, Dr. Chittenden was the President, Chief Technology Officer, and Founding Director of the AI/ Scientific
Machine Learning (SciML) Research and Development Initiative at HiberCell. Under his guidance, HiberCell launched the QuAD³ (Quantum
Artificial Intelligence Drug Discovery and Development) Platform, setting new standards in the field. Dr. Chittenden's career also
includes significant contributions to Genuity Science, a wholly owned subsidiary of HiberCell, where he held multiple leadership roles,
including President, Chief Technology Officer, and Founding Director of the Genuity Artificial Intelligence Research Institute.
are incredibly excited to welcome Dr. Chittenden to our team," said Vin Singh, CEO of BullFrog AI. "His outstanding contributions
to the fields of AI, machine learning, and biostatistics, combined with his leadership in scientific research and development, make him
uniquely qualified to lead our scientific initiatives. We look forward to the advancements in drug development his expertise will bring
to our company and the broader scientific community."
GIGA Society Fellow, Dr. Chittenden has been recognized for his exceptional intellectual contributions and achievements. His work extends
beyond the corporate sector to his role as Chairman, Founding President, and Chief Scientist of the Complex Biological Systems Alliance,
where he has been pivotal in advancing mathematical and theoretical systems biology through global collaborative research.
Chittenden's academic contributions are equally impressive, having served as a Senior Biostatistics and Computational Biology Consultant
at Harvard Medical School, where he consulted for the HMS Research Community on Statistical Sciences and developed courses in Biostatistics
and Computational Biology.
BullFrog AI, Dr. Chittenden will lead the scientific strategy to further develop and implement cutting-edge AI-driven platforms for drug
discovery and development. His vision for integrating AI and machine learning with biostatistics will be crucial in driving BullFrog
AI's mission to accelerate the pace of drug development and bring innovative treatments to patients faster.
Chittenden commented, "I am thrilled to join BullFrog AI and to contribute to the Company's innovative approach to drug development.
The opportunity to apply AI and machine learning technologies to revolutionize how we discover and develop new therapies is incredibly
exciting. I look forward to working with the talented team at BullFrog AI to make significant strides in this dynamic field."
Chittenden's appointment as Chief Scientific Officer of BullFrog AI, effective February 26, 2024, marks a significant milestone
for the Company as it continues to pioneer a new era of AI technology-enabled drug development. His leadership and expertise are expected
to propel BullFrog AI to new heights in its mission to transform the landscape of drug discovery and development.
AI is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development
of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven
drug development using its proprietary bfLEAP artificial intelligence platform to create and analyze networks of biological, clinical,
and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP for use at several
critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall
development costs by decreasing failure rates for new therapeutics.
more information visit BullFrog AI at:
press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about
future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those
that use terminology such as "may," "should," "expects," "anticipates," "contemplates,"
"estimates," "believes," "plans," "projected," "predicts," "potential,"
or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider
various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially
from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press
release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives might not occur.
RedChip Companies, Inc.
BullFrog AI Holdings, Inc.